Lactobacillus rhamnosus Lcr35 as an effective treatment for preventing Candida albicans infection in the preclinical model Caenorhabditis elegans - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2019

Lactobacillus rhamnosus Lcr35 as an effective treatment for preventing Candida albicans infection in the preclinical model Caenorhabditis elegans

Cyril Poupet
Taous Saraoui
Muriel Bonnet
Marylise Gachinat
  • Fonction : Auteur
  • PersonId : 1207295
Olivier Camarès
  • Fonction : Auteur
  • PersonId : 1207294
Christophe Chassard
  • Fonction : Auteur
  • PersonId : 1148060
Adrien Nivoliez
  • Fonction : Auteur
  • PersonId : 1039357

Résumé

Introduction and aims The increased recurrence of Candida albicans infections is associated with greater resistance to antifungal drugs. This involves the establishment of alternative therapeutic protocols such as the use of probiotic microorganisms whose antifungal potential has already been demonstrated using preclinical models (cell cultures, laboratory animals) and clinical studies. Understanding the mechanisms of action of probiotic microorganisms has become a strategic need for the development of new therapeutics for humans. In this study, we investigated the prophylactic anti-Candida albicans properties of Lactobacillus rhamnosus Lcr35® using the in vivo Caenorhabditis elegans model. Materials and methods For this, we followed the survival of the nematode in the case of a fungal infection, prevented or not by the probiotic Lcr35®. This followed by a gene expression analysis. Also, we are interested in the localization of the DAF-16 transcription factor. Results, discussion and conclusion On the top of having a pro-longevity activity in the nematode, Lcr35® protects the animal from the fungal infection even if the yeast is still detectable in its intestine. At the mechanistic level, we note the repression of genes of the p38 MAPK signaling pathway and genes involved in the antifungal response induced by Lcr35® suggesting that the pathogen no longer appears to be detected by the worm immune system. However, the DAF-16 / FOXO transcription factor, implicated in the longevity and antipathogenic response of C. elegans, is activated by Lcr35®. These results suggest that the probiotic strain acts by stimulating its host via DAF-16, but also by suppressing the virulence of the pathogen. However, for more precision, an exhaustive study of the C. elegans transcriptome will be carried out in order to decipher the mechanisms of action of Lcr35®.

Domaines

Bactériologie
CyrilPoupet_SFM_v3.pdf (1.64 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03408319 , version 1 (15-11-2021)
hal-03408319 , version 2 (16-01-2023)

Identifiants

  • HAL Id : hal-03408319 , version 2

Citer

Cyril Poupet, Taous Saraoui, Philippe Veisseire, Muriel Bonnet, Marylise Gachinat, et al.. Lactobacillus rhamnosus Lcr35 as an effective treatment for preventing Candida albicans infection in the preclinical model Caenorhabditis elegans. 15ème congrès national de la SFM, Sep 2019, Paris, France. ⟨hal-03408319v2⟩
36 Consultations
29 Téléchargements

Partager

Gmail Facebook X LinkedIn More